US FDA expands age group for GSK Boostrix Tdap vaccine to include elderly
This article was originally published in Scrip
Executive Summary
The US FDA approved GlaxoSmithKline's tetanus, diphtheria and pertussis vaccine Boostrix as the first and only product in the US to protect elderly adults 65 or older from all three of those diseases in one single booster shot.